Related Experiment Video
Updated: Jun 7, 2025
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity
Yu Zhang1, Yangyang Li2, Zhengfeng Zhang1
1Biomedical Sciences and Health Laboratory of Anhui Province, Division of Life Sciences and Medicine, Hefei National Research Center for Physical Sciences at the Microscale, School of Basic Medical Sciences, The Institute of Immunology and The CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, Hefei, China.
Abstract:
Approximately 70% of patients receiving immune checkpoint blockade therapies develop treatment resistance. Thus, there is a need for the identification of additional immunotherapeutic targets. CD49a is a membrane protein expressed on NK cells and T cells. In this study, we found that CD49a was highly expressed on the surface of tumor-infiltrating NK cells in various mouse tumor models and that CD49a+ tumor-infiltrating NK cells were more exhausted than CD49a- tumor-infiltrating NK cells. Furthermore, CD49a or NK-specific CD49a deficiency slowed tumor growth and prolonged survival in several mouse tumor models, primarily through the essential role played by NK cells in antitumor activities. Blockade of CD49a using an mAb suppressed tumor development in mice, and combination treatment with anti-PD-L1 further enhanced antitumor efficacy. Our research reveals CD49a on NK cells as an immunotherapeutic target and highlights the potential clinical applications of CD49a-targeted therapies.
Insights
Researchers identified CD49a, a protein on Natural Killer (NK) cells, as a promising target for cancer immunotherapy. Blocking CD49a on NK cells can enhance anti-tumor responses and overcome treatment resistance.
Area of Science:
- Immunology
- Cancer Biology
- Cellular and Molecular Immunology
Background:
- Immune checkpoint blockade (ICB) therapies are limited by ~70% treatment resistance.
- Novel immunotherapeutic targets are crucial for improving cancer treatment efficacy.
- CD49a is a membrane protein found on Natural Killer (NK) and T cells.
Purpose of the Study:
- To investigate the role of CD49a on tumor-infiltrating NK cells in cancer.
- To evaluate CD49a as a potential immunotherapeutic target for enhancing anti-tumor immunity.
Main Methods:
- Analysis of CD49a expression on tumor-infiltrating NK cells in mouse models.
- Assessment of NK cell exhaustion markers in CD49a+ versus CD49a- populations.
- Evaluation of tumor growth and survival in mice with CD49a deficiency or CD49a blockade.
- Combination therapy studies with anti-PD-L1.
Main Results:
- CD49a was highly expressed on tumor-infiltrating NK cells across various mouse tumor models.
- CD49a+ NK cells exhibited increased exhaustion compared to CD49a- NK cells.
- Genetic deletion or antibody blockade of CD49a suppressed tumor growth and improved survival.
- Combination therapy of CD49a blockade with anti-PD-L1 demonstrated enhanced anti-tumor efficacy.
Conclusions:
- CD49a expressed on NK cells represents a viable immunotherapeutic target.
- Targeting CD49a holds potential for overcoming ICB resistance and improving cancer treatment outcomes.
- CD49a-targeted therapies may offer a novel strategy for enhancing anti-tumor immunity.
More Related Videos
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...